Atox Bio’s Tissue Infection Treatment Fast-Tracked By FDA

The FDA has granted Israeli company Atox Bio’s tissue infection treatment AB103 fast track status. AB103 is designed to treat Necrotizing Soft Tissue Infections. The company will begin testing on 40 patients, suffering from the condition, which causes severe infection to the skin. There is currently no approved treatment for the condition.